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Introduction The aetiology of congenital hearing loss 
is heterogeneous, and in many infants a genetic cause 
is suspected. Parents face a diagnostic odyssey when 
searching for a cause of their infant’s hearing loss. 
Through the Melbourne Genomics Health Alliance, a 
prospective cohort of infants will be offered whole-exome 
sequencing (WES) with targeted analysis in conjunction 
with chromosome microarray to determine the genetic 
causes of congenital hearing loss. Parents will also be 
offered the opportunity to receive additional results from 
their infant’s WES. 
Methods Eligible infants will be identified through the 
Victorian Infant Hearing Screening Program and offered 
an appointment in a paediatrician-run clinic, a genetics 
assessment and enrolment in the Victorian Childhood 
Hearing Impairment Longitudinal Databank. If parents 
consent to WES, genes causing deafness will be analysed 
and they can choose to obtain additional findings. For 
the additional results component, a modified laboratory 
protocol has been designed for reporting of results in the 
absence of a relevant phenotype. Parents’ experience of 
being offered WES will be evaluated using surveys. 
Discussion This project will provide descriptive analysis 
of the genetic aetiology of congenital hearing loss in this 
cohort and may provide data on genotype–phenotype 
correlations. Additionally, choices regarding additional 
findings will be analysed. Participants will represent a 
diverse cross section of the population, increasing the 
ability to generalise results beyond the study group. 
Evaluation surveys will allow analysis of preferences 
around counselling, usefulness of a decision aid and 
adequacy of information provision.
IntroDuctIon
Congenital hearing loss affects 0.1% of the 
Australian population. Universal newborn 
hearing screening has lowered the mean 
age of detection of moderate to profound 
hearing loss to around 2 months of age1 2 and 
early identification of hearing loss allows early 
amplification (hearing aids and cochlear 
implants) and early intervention3 to improve 
cognitive and communication development.
Although the aetiology of congenital 
hearing loss is heterogeneous, a significant 
proportion has a genetic basis.4 Several 
hundred genes have been identified as playing 
a role in hearing and all modes of inheritance 
What this study hopes to add?
 ► Descriptive evidence of what proportion of 
congenital hearing loss is due to a genetic aetiology 
and what the genetic causes are in this cohort.
 ► A streamlined approach for information delivery 
and comprehensive care for parents who have a 
newborn diagnosed with hearing loss.
 ► An opportunity to investigate if, why and how 
people want additional findings when they have 
genomic sequencing in their children.
Strengths and limitations of this study
 ► Strengths are that this is a population based study 
with the potential to provide actionable results 
for families, that the study is integrated into a 
pre-existing framework, and that it will also provide 
evidence around the scope of results that should be 
returned for genomic sequencing. 
 ► Limitations are genomic testing may not identify all 
genetic causes of hearing loss.
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Protocol
What is already known in this topic?
 ► 50% of congenital bilateral moderate or worse 
hearing loss is presumed to have a genetic 
aetiology.
 ► Many individuals do not receive a genetic diagnosis 
due to the heterogeneous nature of the disease and 
the expense of iterative gene testing.
 ► A majority of individuals, including parents, 
are interested in receiving additional genomic 
information when they have next-generation 
sequencing performed as a diagnostic test.
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are described: autosomal dominant, recessive, x-linked 
and mitochondrial.5 Congenital hearing loss is most 
commonly an isolated finding; however, in 30% there is 
an associated syndrome diagnosis.5 Syndromic associa-
tions may not be evident until later childhood or adult-
hood, for example in Usher syndrome, which results in 
retinitis pigmentosa and visual loss starting in the later 
childhood years.
Despite the high frequency of an underlying genetic 
aetiology, few families receive a genetic diagnosis 
because of the iterative nature of single gene testing and 
the significant expense and time required to engage in 
this process. Whole-exome sequencing (WES) allows 
simultaneous and rapid analysis of human genes, there-
fore detection of all exome tractable mutations in genes 
known to be associated with deafness should be possible 
for these patients. Benefits of receiving an early genetic 
diagnosis include provision of prognostic information, 
streamlined care, accurate recurrence risk advice, and 
where appropriate, screening for associated health 
conditions.
Through the Melbourne Genomic Health Alliance 
(the Alliance), WES will be offered in a clinical context to 
a 2-year prospective population-based cohort of patients 
diagnosed in the newborn period with hearing loss. Estab-
lished as a collaboration in 2013, the members of the Alli-
ance are 10 healthcare, education and medical research 
institutions committed to incorporating genomics into 
healthcare to benefit patients.6 This project is part of 
the Alliance’s broader programme of work to develop an 
evidence base to inform the cost-effective use of genomics 
in clinical practice and to build workforce capability in 
Victoria, Australia.6 Alliance processes, procedures, and 
systems are technically agnostic, that is, they are designed 
to be modifiable as utility in routine clinical practice is 
demonstrated for other ‘-omic’ technologies. WES with 
targeted analysis,  the first of these technologies, is ready 
for clinical application. Congenital hearing loss is an ideal 
candidate condition to further this work because of its 
extensive genetic heterogeneity, and a population-based 
cohort is readily identifiable.
In line with international research on the implemen-
tation of genomic sequencing7 8 this cohort of infants 
will be used to investigate parents’ preferences around 
receipt of additional genomic information about their 
newborn. This will help inform the scope of genomic 
sequencing results provided to families and may provide 
baseline data to inform studies of genomic sequencing in 
healthy newborns.
Studies of the return of results from genomic sequencing 
have indicated that the majority of individuals express a 
desire for additional genetic information.8–10 Hypothet-
ical preferences for return of additional information 
indicate that a large proportion (>80%) of survey respon-
dents from the Melbourne Genomics demonstration 
project want this information for preventable conditions 
(C. Gaff, unpublished data, 2017). We will contribute to 
this pool of research, with this study having the benefit of 
recruiting a population sample with diversity of ethnicity, 
language, socioeconomic status and education level.
stuDy AIMs AnD hypothesIs
The primary aims of the Melbourne Genomics Congen-
ital Deafness project are to understand the reasons 
parents choose to have genetic testing for their infant 
and to describe the genetic aetiologies that cause 
congenital hearing loss in this cohort. A secondary aim is 
to investigate the feasibility and acceptability of genomic 
screening of newborns for other health conditions that 
occur in childhood. This component of the study is titled 
‘Baby Beyond Hearing’.
The study hypotheses are that: (1) the majority of 
parents will choose to have WES for their child because 
accurate genetic diagnosis at an early age will benefit 
families (understanding the cause, recurrence risk and 
prognosis information) and health systems (limiting the 
need for further investigation and tailoring screening as 
indicated by the genetic diagnosis), (2) up to 50% of chil-
dren born with moderate or worse bilateral permanent 
hearing loss will have a genetic cause identifiable by a 
combination of WES and microarray and (3) parents will 
want to receive additional genetic information from the 
WES data about their children.
MethoDs/DesIgn
The state of Victoria, Australia, has a unique infrastruc-
ture of three major platforms that jointly enable this 
study to be conducted at the population level, as follows:
Victorian Infant hearing screening program (VIhsp): 
identification and recruitment
The VIHSP is a well-established state-wide newborn 
hearing screening programme delivered in all birthing 
hospitals via a single provider, the Royal Children’s 
Hospital, Melbourne. The programme commenced 
in 2005 and by 2012 established state-wide coverage of 
approximately 80 000 births annually. All newborns are 
offered automated auditory brainstem response (AABR) 
testing. Those who do not pass the first screening test are 
referred for a repeat AABR, with a second positive screen 
result leading to a referral to audiology for confirmatory 
diagnosis.2 Based on VIHSP data from previous years, it 
is estimated that 140 patients will meet the criteria for 
entry into the study over this 2-year period.11 There are 
no similar studies or empirical data on which to predicte 
uptake and therefore sample size.
Victorian childhood hearing Impairment Longitudinal 
Databank (VicchILD): recruitment, programme evaluation, 
long-term outcomes
VicCHILD is a longitudinal databank for Victorian chil-
dren diagnosed with hearing loss. This programme 
follows children and families over time to: (1) help 
researchers and health professionals gain a better 
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understanding of the causes and outcomes of childhood 
hearing loss, (2) understand why some children do well 
while others face greater difficulties and (3) improve 
intervention and treatment and ultimately the lives of 
children with permanent hearing loss and their families. 
Over the 2-year period prior to this project commencing 
VicCHILD identified that of babies born with congenital 
hearing loss, 40% of their parents were born overseas 
with the majority of these being of Asian ethnicity and 
20% of families identified a primary language other than 
English. Families came from a range of socioeconomic 
backgrounds. This provides an insight into the diversity 
of the cohort that will be recruited in this project.
paediatrician clinics: recruitment, phenotyping, long-term 
outcomes
Two clinical services exist in Victoria, specifically catering 
to infants diagnosed with hearing loss through VIHSP. 
These are run through two of the major tertiary hospitals 
in the state. The Paediatric Hearing Loss Investigation 
Clinic (PHLIC) through Monash Children’s Hospital 
and the Caring for Hearing Impaired Children (CHIC) 
clinic through the Royal Children’s Hospital.
Eligibility criteria
Infants born between January 2016 and December 2017 
(inclusive) in Victoria and diagnosed, following two 
positive AABR screens delivered by VIHSP, with bilateral 
permanent hearing loss greater than 40 dB over three 
frequencies (moderate, severe or profound hearing 
loss). These criteria include infants classified as having 
sensorineural, mixed conductive and sensorineural and 
auditory neuropathy. These infants may have isolated 
hearing loss or suspected syndromic hearing loss.
Exclusion criteria
Unilateral hearing loss of any degree or mild hearing loss 
or better in the best ear or hearing loss that is confirmed 
as conductive and temporary.
recruItMent proceDures
Recruitment procedures are depicted in figure 1.
opt-out letter
Infants who fulfil the eligibility criteria will be identi-
fied by VIHSP and sent an ‘opt-out’ letter, which briefly 
outlines the paediatrician-run clinics, VicCHILD and 
the Melbourne Genomics Congenital Deafness project. 
Parents will be given the option of doing nothing and 
therefore being contacted over telephone, sending an 
‘opt-out’ notification back to VIHSP (via prepaid post, 
email or fax) or deferring contact by several months.
telephone call
A genetic counsellor or genetic doctor will telephone 
parents who do not opt-out and provide standardised 
information using a guideline. Parents will be offered an 
appointment in CHIC or PHLIC clinic. They will be able 
to book a genetic counselling appointment to discuss 
genetic testing on the same day or at an alternate time 
according to their preference.
Information about VicCHILD will also be provided 
and parents will be given the opportunity to meet with a 
VicCHILD staff member on the day of their appointment.
Interpreter services will be available for families from 
a non-English speaking background. If the family is not 
contactable over telephone, alternative attempts will be 
made such as via email or by review of the medical record 
(if one exists) for an alternative contact number.
At the phone call, parents indicate which of the three 
initiatives (VicCHILD, Melbourne Genomics and paedia-
trician clinics) they wish to pursue. For patients who book 
an appointment for genetic counselling, an information 
pack will be sent in the post, including a questionnaire 
and a decision aid. Both parents are encouraged to attend 
the appointment to facilitate joint decision-making.
bAseLIne questIonnAIre
The questionnaire was designed in collaboration with the 
paediatricians providing the CHIC and PHLIC clinics and 
the VicCHILD research team. The questionnaire enables 
parents to complete a single document that provides the 
necessary information for: (1) the clinical appointment, 
(2) inclusion in VicCHILD and (3) data collection for 
the Melbourne Genomics Congenital Deafness project. 
Parents can opt to share this information with all three 
initiatives or exclude any in which they do not wish to 
participate.
The questionnaire asks about pregnancy, delivery, 
family history, the child’s hearing loss diagnosis, inves-
tigations, treatments and service use to date, general 
health and development (ASQ)12 as assessed by the 
parent, demographic information, quality of life (PEDS 
QL 3.0)13 and parental mental health.14 Parents can 
complete the questionnaire in paper form or online.
DecIsIon AID
A decision aid has been developed specifically for this 
study to provide families with information about testing 
prior to their appointment. The decision aid was modelled 
on a tool designed by the Public Health Genetics team at 
the Murdoch Children's Research Institute for couples 
to use when deciding what investigations to have during 
pregnancy.15 The decision aid helps to ensure parents are 
giving true informed consent for genomic testing, and 
will also be used to evaluate what resources are required 
to integrate genomic sequencing into standard clinical 
practice.16 The decision aid is designed to help families 
consider if they would like their child to have WES, and 
also how much information they would like to receive 
from the test. The document contains two worksheets 
where parents can explore their own personal views on: 
(1) having genetic testing and (2) how much informa-
tion they are interested in receiving from this testing. 
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Figure 1 Flowchart of recruitment and testing. CHIC, Caring for Hearing Impaired Children; PHLIC, Paediatric Hearing Loss 
Investigation Clinic; VIHSP, Victorian Infant Hearing Screening Program.
Infants whose parents consent to investigate the cause of 
hearing loss will be offered options regarding additional 
gene analysis (table 1).
Parents are asked to bring the decision aid to the 
appointment where a genetic counsellor will go through 
their preferences and use the document as a talking point 
for exploring their decisions around genetic testing.
cLInIc AppoIntMent
A paediatrician with special interest in hearing loss and 
either a doctor with training in genetics or a genetic 
counsellor will conduct the clinic appointment. During 
the first hour of the appointment, the patient will have 
a full clinical and developmental assessment and non-ge-
netic investigations and referrals will be ordered as 
5Downie L, et al. BMJ Paediatrics Open 2017;1:e000119. doi:10.1136/bmjpo-2017-000119
Open Access
Table 1 The three choices offered to parents regarding which genes will be analysed and reported following whole-exome 
sequence
Choice A Choice B Choice C
Only genes that are known 
to cause hearing loss will be 
examined. We estimate that we 
will identify a genetic cause for 
hearing loss in about half of the 
infants that we test.
Choice B is the same as Choice A 
 
plus 
 
We will analyse additional genes that 
cause diseases that:
1. affect children 
2. have a known treatment or 
intervention that will improve the 
child’s health.
Choice C is the same as Choice B 
 
plus 
 
We will analyse additional genes that cause 
diseases that:
1. affect children
2. may not have a clear treatment pathway or 
intervention to improve the child’s health.
indicated. During the second hour of the appointment, 
a genetic counsellor will discuss WES with the parents in 
more detail, using the completed decision aid as a basis 
for discussion.
Talking points for genetic counsellors will be created in 
addition to a training session facilitated by an educator 
and experienced genetic counsellors to upskill counsel-
lors in obtaining consent for additional findings. This 
ensures that the information and counselling provided 
is standardised across sites and between clinicians. If 
the family wishes to participate in the research, clinical 
grade WES and chromosome microarray will be ordered 
and a venous blood sample will be taken from the child 
on the day. Families will also have the option of having 
more time to consider the testing with follow-up from the 
genetic counsellor.
Written consent will be required to participate in the 
study from one parent; however, counsellors will ensure 
that both parents are aware of the nature of the testing 
and in agreeance regarding the scope of results to be 
returned.
Appointments to disclose results will be scheduled 
when reports are issued for the WES. These may be with 
a geneticist or paediatrician and genetic counsellor.
gene lists
Gene lists are designed to allow rapid interpretation of 
test data as well as filtering of unwanted information such 
as variants in genes known to cause adult-onset untreat-
able disease (online supplementary appendix 1).
Choice A contains all of the genes known to cause 
hearing loss. It was constructed by comparing and 
merging gene lists from two pre-existing clinical diag-
nostic panels: OtoSCOPE17 and OtoGenome,18 and 
several research gene lists sourced from Genomics 
England (the PanelApp Congenital Hearing Impairment 
(profound/severe) panel v1.8),19 the Avraham labora-
tory,20 the Gasparini laboratory21 and the Rehm labora-
tory.22 Additional genes were added to the list based on 
recently reported findings in the literature. The list is 
separated into two tiers. Tier 1 comprises 141 genes for 
which there is validated evidence that mutations are caus-
ative in human patients with hearing loss. Tier 2 contains 
a further 241 genes with good evidence from a range of 
sources for their involvement in hearing loss, substan-
tively based on evidence from animal models.
Choice B was adapted from a gene list created, and 
generously shared, by the NC NEXUS group. This list is 
based on a metric they devised and used to ‘score’ gene/
disease pairs.23 These conditions all have treatment or 
intervention available.
Choice C was devised using a set of criteria that were 
agreed by the investigative team. These include:
 ► definitive gene disease association (as defined by the 
BabySeq group10);
 ► onset of symptoms prior to age 16 the majority of the 
time;
 ► validation method available to confirm diagnosis at 
the time of testing.
All of the diseases associated with genes in choice C 
have a validation method available such as a biochemical 
test, X-ray or a one-off clinical examination in order to 
provide additional certainty around a presymptomatic 
diagnosis.
LAborAtory protocoL
Exome sequencing, variant detection, variant filtering 
and interpretation will be performed in a clinically 
accredited laboratory using similar methods to those 
previously described in other patient cohorts of the 
Melbourne Genomics Health Alliance.24
Whole-exome sequencing
DNA will be extracted from peripheral blood, and exome 
sequencing will be performed using SureSelect Clinical 
Research Exome V.1 (Agilent) on either a HiSeq4000 
or NextSeq500 (Illumina) with a targeted average 
sequencing depth of 100×.
bioinformatic analysis and variant filtering
Data analysis and variant calling will be performed using 
Cpipe.25 Variants will be assessed using LOVDplus.26 
Variants will be prioritised based on the clinician’s assess-
ment using information such as likely mode of inher-
itance (assumed to be autosomal recessive unless family 
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history indicates otherwise) and any phenotypic informa-
tion available such as MRI brain findings or dysmorphic 
features on examination. We predict a large proportion 
of patients will have no family history and no additional 
phenotypic information apart from hearing loss and in 
this instance all variants detected will be curated.
Variant interpretation
The methodology around the interpretation of the addi-
tional findings gene lists focuses on the shift in principle 
from using WES as a diagnostic tool to use of WES as a 
screening tool. In a diagnostic situation, a high level of 
sensitivity is required from the test to capture all possible 
causes of a patient’s phenotype. In a ‘screening’ or 
‘predictive’ analysis, a high level of specificity is required 
to ensure there is adequate evidence and understanding 
of the outcome of a gene variant to return results to 
patients who will often be asymptomatic at that time.
The standard diagnostic laboratory variant interpre-
tation protocol was adapted for this cohort due to the 
novel situation of offering analysis of genes outside of the 
patient’s current phenotype.
Choice A, tier 1 genes will be analysed in accordance 
with the laboratory’s National Association of Testing 
Authorities accredited procedures which are aligned 
with American College of Medical Genetics guidelines,27 
resulting in a clinical report. Choice A, tier 2 genes will 
be analysed by a research group only in patients who do 
not receive a clinical result from tier 1.
Choice B and C genes will be analysed by the same clin-
ically accredited diagnostic laboratory for patients who 
consented to the analysis, but only variants in class 4 or 
528 will be reported to families for these genes. Variants of 
uncertain significance, as well as carrier-only variants, will 
not be reported. In order for this process to be stream-
lined, any missense variant identified in the genes of 
interest will first be searched for in the literature. If the 
variant is not previously described in published literature 
or in ClinVar, no further curation will be performed. This 
is on the basis that missense variants cannot be classified 
any higher than class 3 without supporting case reports. 
Truncating and nonsense variants are curated in the 
same way as variants in choice A.
Criteria for classification will be based on the principles 
outlined in the American College of Medical Genetics 
and Genomics standards for interpretation of sequence 
variants.27 Variant classifications will be reviewed in a 
multidisciplinary team meeting attended by clinical 
geneticists and other medical subspecialists, genetic 
counsellors, molecular geneticists and bioinformaticians.
eVALuAtIon surVeys
Evaluation surveys have been designed and can be 
completed online or on paper. Patients will complete 
the first survey 2 weeks after they consent for genomic 
testing and a second survey 2 weeks following their 
results appointment (see figure 1). The surveys include 
data captured for Melbourne Genomics across all 
patient groups as well as data that is specific to children 
within the Melbourne Genomics Congenital Deafness 
project.
The first survey includes questions about the parents’ 
experience of the consent process including the deci-
sion aid and the genetic counselling appointment. The 
Decisional Conflict Scale and Decisional Regret Scales29 
are included in survey 1 and 2, respectively, to evaluate 
parental decision-making around which gene list they 
selected for analysis. The first survey includes closed and 
open questions exploring families’ reasons for wanting 
to have genomic sequencing for their child. Knowledge 
questions and a question on the likelihood of the test 
finding the cause of the hearing loss are included to 
gauge understanding. Validated measures to assess poten-
tial predictors of uptake of the expanded analysis are 
included: tolerance of uncertainty,30 State-Trait Anxiety 
scale,31 medical literacy32 and information-seeking pref-
erences.33 34 The Perceived Personal Control scale35 is 
included as a measurement of patient empowerment in 
both surveys.
The second survey includes study-specific questions 
assessing the parents’ understanding of the genomic 
results, impact these will have on them and their family 
and what they have valued about having the test done for 
their child.
AnALysIs of DAtA
The majority of data analysis will be descriptive in nature 
due to the small sample size, which is estimated to be 
approximately 100. The primary outcome measures 
reported will be uptake of testing, the detection rate 
of causative/pathogenic variants and identification of 
carrier status. Detailed sociodemographic characteris-
tics of the participants (eg, socioeconomic status, age of 
parents, language and cultural background, education) 
and variable aspects of the process and outcomes will be 
presented, followed by comparisons between groups of 
interest. Examples of these include:
1. information delivery methods (phone call, face-to-face 
consultation and written information) and parental 
responses to the offer of testing and their knowledge 
about testing in relation to these various modalities;
2. psychosocial measures of parents who accept versus 
decline testing and the scope of results chosen by 
those who participate;
3. differences in uptake between parents of children who 
require cochlear implant, those who are systemically 
unwell or have a broader phenotype (not isolated 
hearing loss) or whose infant was born prematurely 
for example.
Multivariable statistical analysis may be performed, but 
this will be dependent on sample size for each group, 
for example, accept testing versus decline testing and no 
additional findings versus additional findings.
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Audiological and general phenotype data will be 
correlated with genotype and a summary of these find-
ings will be presented.
DIscussIon
This project is novel in offering genomic sequencing to 
infants with congenital hearing loss in conjunction with 
comprehensive developmental and general health assess-
ments and long-term follow-up.
The primary strengths of the study are that it is a popu-
lation-based study, has the potential to provide actionable 
results for families at an early stage and is integrated into 
a pre-existing framework, making the process stream-
lined for patients and care providers. It will also provide 
new and important evidence around the scope of results 
that should be returned for genomic sequencing. The 
limitations of the study are concordant with the limita-
tions of all WES. These relate to sequencing gaps which 
may result in a pathogenic variant not being detected, 
as well as the technology’s inability to detect some types 
of DNA changes such as copy number variation, and the 
possible detection of a variant in a gene that is not yet 
known to have an association with hearing loss. Evidence 
suggests a significant proportion of congenital hearing 
loss (15%–20%) is due to copy number variants36 and for 
this reason, all patients will simultaneously have a chro-
mosome microarray.
Genomic results will add to the knowledge around 
the genetic aetiology of congenital hearing loss and will 
provide important data on genotype–phenotype correla-
tions. The use of genomic sequencing means that fami-
lies who do not receive a molecular diagnosis initially can 
participate in research around genes related to hearing 
loss and enable gene discovery in this area by having their 
child’s WES data reanalysed.
Descriptive analyses of parents’ interest in gaining 
additional results from genomic sequencing will provide 
novel information that will help to determine the clin-
ical utility of an offer to provide sequencing results 
beyond those directly related to the child’s phenotype, 
that is, deafness in this case. The study will assess previ-
ously described concepts, for example, what has been 
described as ‘inflicted ought’ where parents have a desire 
to do what they believe is the best thing for the child 
despite the individuals not necessarily seeking similar 
predictive information for themselves.37 It will also 
provide important data on parents’ decisions when faced 
with the reality of testing. Previous studies have found 
that parent preferences when offered theoretical versus 
actual testing can produce quite disparate results. In the 
BabySeq study, a large proportion of parents indicated 
in preparatory research that they would be interested in 
genomic sequencing for their newborn;10 however, in 
reality the uptake for the study has been very low.38
Evaluation surveys will produce data for further descrip-
tive analysis of preferences around counselling, use of a 
decision aid and the information provided. Together, 
these results will add substantially to the development 
of strategies and policies related to implementation of 
genomic sequencing in the newborn period.
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